Pre-treatment with CD37 Antibody Enhances Amount of Betalutin to NHL Tumors, Study Finds

Pre-treatment with CD37 Antibody Enhances Amount of Betalutin to NHL Tumors, Study Finds

Preliminary trial results show that pre-treatment with the antibody lilotomab may increase the amount of Nordic Nanovector‘s investigational therapy Betalutin that reaches tumor lesions in patients with non-Hodgkin’s lymphoma (NHL).

Representatives from Nordic Nanovector presented their findings at the European Association of Nuclear Medicine annual meeting held Oct. 21-25 in Vienna, Austria.

The oral presentation was titled, “Pre-dosing with Lilotomab Prior to Antibody-Radionuclide Conjugate Therapy with 177Lu-Lilotomab Satetraxetan Significantly Increases the Ratio of Tumour to Red Marrow Absorbed Dose in non-Hodgkin Lymphoma Patients.”

Betalutin is a novel CD37-binding antibody that is labeled with a type of radiation — the beta-emitter lutetium-177 (177Lu). CD37 is highly elevated on most B-cell malignancies, including NHL, making it a promising therapeutic target.

By linking the CD37 antibody with 177Lu, radiation can be specifically targeted toward the tumor mass. The beta-radiation facilitates a localized killing of the tumor mass, including cells with or without the CD37 protein. This approach has some advantages over other targeted therapies.

In a Phase 1 trial called LYMRIT-37-01 (NCT01796171), researchers evaluated the uptake of increasing amounts of Betalutin in tumor lesions with or without pre-treatment with lilotomab, the antibody that targets CD37.

Because the protein CD37 is also found in healthy immune cells, Betalutin is linked with hematological toxicity. Lilotomab pre-dosing was expected to lessen this toxicity by reducing the amount of Betalutin that binds to healthy bone marrow cells.

The study included 14 patients with a total of 35 tumor lesions. Using single-photon emission computed tomography (SPECT/CT), a 3D imaging technique that detects gamma radiation in the body, researchers measured the amount of Betalutin in the bone marrow and tumors.

In patients pre-treated with lilotumab, the amount of Betalutin in the bone marrow was significantly lower (35% to 40%) compared to patients who did not receive the pre-treatment. Also, tumor doses were significantly higher among those who received pre-treatment.

“Pre-dosing with lilotomab has a mitigating effect on red marrow absorbed dose for 177Lu-lilotomab satetraxetan patients, and increased pre-dosing amounts was found correlated with a higher tumor dose,” the researchers wrote.

“While the optimal amount of lilotomab is yet to be investigated, both pre-dosage levels significantly increased the tumor to RM [red marrow] absorbed dose ratio.”

Nordic Nanovector’s main investigational therapy in clinical trials is the antibody-radionuclide conjugate Betalutin. This therapy is currently being evaluated in several clinical trials, alone or in combination with other therapies, for the treatment of non-Hodgkin’s lymphoma and relapsed, refractory follicular lymphoma.

How useful was this post?

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?